Cisplatin dosing
Cisplatin dosing, indications, interactions, adverse effects, and more
The dosage is based on your medical condition, body size, and response to treatment.During treatment with this medication, it is important that you take in more ...
CISplatin Injection - accessdata.fda.gov
Cisplatin Injection infusion concentrate must be further diluted prior to administration (see. DOSAGE AND ADMINISTRATION, All Patients). The active ingredient, ...
Cisplatin - StatPearls - NCBI Bookshelf
Administration · Advanced testicular cancer: 20 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle. · Advanced bladder ...
DBL Cisplatin Data Sheet - Medsafe
It may be employed, in appropriate circumstances, in addition to other modalities, e.g. radiotherapy or surgery. 4.2 Dose and method of administration. Dosage.
Cisplatin Dosage Guide + Max Dose, Adjustments - Drugs.com
Usual Adult Dose for Testicular Cancer: 20 mg/m2 by slow IV infusion daily for 5 days per cycle in combination with other approved chemotherapeutic agents.
cisplatin injection - accessdata.fda.gov
Consider dose reductions or alternative treatments in patients with renal impairment [see Dosage and Administration (2.1) and Warnings and Precautions (5.1)]. •.
DRUG NAME: Cisplatin - BC Cancer
should be taken to avoid overdosing such as writing the cisplatin dose as a daily dose, not as a total cisplatin dose used in one course of ...
Cisplatin (intravenous route) - Mayo Clinic
Cisplatin injection is used to treat advanced cancer of the bladder, ovaries, or testicles. Cisplatin is an antineoplastic agent (cancer ...
PRODUCT INFORMATION – CISPLATIN INJECTION ... - Pfizer
To minimise the risk of nephrotoxicity, hydrate before, during and after therapy (see Section. 4.2 Dose and method of administration). Prior to initial therapy, ...
CISplatin - Cancer Care Ontario
They occur in 28-36% of patients treated with a single dose of 50mg/m2. Renal toxicity may be permanent with high doses or prolonged treatment. Nephrotoxicity ...
Low dose cisplatin weekly versus high dose cisplatin every three ...
Conclusions. Low SMM is predictive for CDLT in HNSCC patients receiving triweekly cisplatin in combination with radiotherapy with curative ...
Cisplatin: Uses, Side Effects, Dosage & Reviews - GoodRx
Cisplatin can be used by itself, but it's also often used with other anticancer medications. Cisplatin is given as an infusion through the vein by a healthcare ...
Once-a-Week Versus Once-Every-3-Weeks Cisplatin ...
In locally advanced head and neck squamous cell carcinoma (LAHNSCC), high-dose (100 mg/m2) once-every-3-weeks cisplatin added to curative ...
Cisplatin given at three divided doses for three consecutive days in ...
We retrospectively compared toxicity of cisplatin at 75mg/m2 one day versus 25mg/m2 for 3 consecutive days repeated every three weeks focusing on nausea/ ...
Split-Dose Cisplatin in Patients With Locally Advanced or Metastatic ...
The concept of a split-dose cisplatin schedule, in which the standard cisplatin dose is administered over 2 days instead of 1 day, was previously tested in non- ...
Cisplatin Prescription & Dosage Information - MPR - eMPR.com
50–70mg/m 2 IV per cycle once every 3–4 weeks. Heavily pretreated patients: initially 50mg/m 2 IV per cycle every 4 weeks.
Cisplatin nephrotoxicity - UpToDate
Outline · Intravenous saline · Avoidance of potential nephrotoxins · Lower doses of cisplatin · Use of cisplatin analogs · Unclear role for mannitol.
Cisplatin (Cisplatin Injection): Side Effects, Uses, Dosage ... - RxList
Cisplatin is an anti-cancer (antineoplastic) medication used to treat cancers of the testicles, ovaries, or bladder.
High-Dose Cisplatin for Head and Neck Cancer Lives On
The results show that in this patient population, weekly cisplatin is not noninferior to high-dose cisplatin given once every 3 weeks.
Comparison of two different S-1 plus cisplatin dosing schedules as ...
Background. Five-weekly S-1 plus cisplatin (SP5) is one of the standard first-line regimens for advanced gastric cancer (GC), proven in a Japanese phase III ...